Gilead's top line has re-accelerated, with revenue growing 6.8% year over year to $8.3B in Q3 2026 after a weak first half of 2025, and gross margin expanding from 76.9% in Q1 2025 to 81.1%, supported by its high-margin HIV franchise.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue grew 6.8% to $8.3B in Q3 2026 with a 41.7% operating margin, though the Q2 2026 impairment-driven loss of $10.5B warrants continued scrutiny of earnings quality.
Gilead is expected to launch four new products in 2026, including anito-cel CAR T-cell therapy with a 96% response rate, awaiting FDA approval.
Gilead's HIV business, led by treatments like Biktarvy, remains a significant revenue driver, with lenacapavir receiving funding for expanded access.
The acquisition of Arcellx enhances Gilead's oncology pipeline, indicating a strategic shift beyond its traditional HIV focus.
Recent large acquisitions may complicate integration, risking financial performance and investor confidence.
The success of new products like Yeztugo and anito-cel is not guaranteed, and any sales shortfall could compress stock prices.
Significant investments in acquisitions have led to high debt, raising concerns in a rising interest rate environment.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $2.55+16.4% vs $2.19 | $8.3B+6.3% vs $7.8B |
Q3 2026 Aug 4, 2026 | -$6.75+6.9% vs -$7.25 | $7.8B+5.5% vs $7.4B |
Q2 2026 May 7, 2026 | $2.03+6.3% vs $1.91 | $7.0B+0.7% vs $6.9B |
Q1 2026 Feb 10, 2026 | $1.86+2.8% vs $1.81 | $7.9B+3.1% vs $7.7B |
A red ink EPS figure usually spells trouble for retirees counting on a payout. Gilead's loss traces back to one strange quarter, and a single cash metric reveals whether the dividend checks are really at risk.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi® (seladelpar) achieved the alkaline phosphatase (ALP) normalization composite endpoint defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥ 15% decrease from baseline. ALP is a key marker of disease activity and long-term outcomes in PBC. The.
Gilead's HIV therapies generate strong free cash flow. The company is successfully branching out into oncology and anti-inflammatory therapies.
Ascent Group LLC cut its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 11.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 56,100 shares of the biopharmaceutical company's stock after selling 7,256 shares during the quarter. Ascent Group LLC's holdings
Benchmark GILD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Gilead Sciences, Inc. (GILD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $166.89 | $207.21B | -54.05 | 2.39% | -12.47% | -21.84% | 1.91% | |
| $291.31 | $514.68B | 49.87 | 8.57% | 15.68% | — | 2.26% | |
| $62.14 | $126.89B | 13.80 | -0.22% | 18.47% | 43.84% | 3.98% | |
| $460.42 | $248.49B | 26.77 | 9.92% | 24.12% | 85.59% | 2.05% | |
| $248.35 | $36.69B | 105.48 | 1.39% | 3.38% | 1.86% | — | |
| $904.35 | $93.17B | 19.82 | 0.99% | 28.51% | 15.07% | 0.38% |
Gilead Sciences, Inc. (GILD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Gilead Sciences, Inc. (GILD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Aug 4, 2026·SEC
May 20, 2026·SEC
Get notified when GILD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Gilead Sciences, Inc. (GILD) stock FAQ — growth, dividends, profitability & financials explained
Gilead Sciences, Inc. (GILD) reported $30.99B in revenue over the trailing twelve months. Revenue was $29.44B in fiscal year 2025. That is 88050% more than the $33.4M of fiscal year 1996.
Gilead Sciences, Inc. (GILD) grew revenue by 6.5% over the trailing twelve months, compared with the twelve months before.
No. Gilead Sciences, Inc. (GILD) reported a net loss of $3.86B over the trailing twelve months.
Yes. Gilead Sciences, Inc. (GILD) pays a dividend that yields 1.91% at the current price, a moderate yield.
Gilead Sciences, Inc. (GILD) had a return on equity (ROE) of -21.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Gilead Sciences, Inc. (GILD) generated $14.04B in free cash flow over the trailing twelve months.
